

## FOR IMMEDIATE RELEASE

### **CRITICAL OUTCOME TECHNOLOGIES INC. ANNOUNCES THE ISSUANCE OF STOCK OPTIONS**

**London, Ontario (November 3, 2008): Critical Outcome Technologies Inc. (TSX Venture: COT)** announced today that the Board of Directors approved the granting of 500,000 stock options under the Company's Stock Option Plan to its newly appointed Chief Executive Officer, Mr. Michael Cloutier, at its Board meeting of October 31, 2008. The options have a life of five years and are exercisable at a price of \$0.50 per share with 20% of the options vesting after the first six months, 20% after one year, 30% after two years and the remaining 30% after three years. The exercise price represents the closing price of the Company's common shares on October 30, 2008, as reported on the TSX Venture Exchange.

"Stock options enhance the Company's ability to attract and retain talented people by providing compensation incentives to employees, directors, officers and consultants for future services provided to the Company," advised Mr. John Drake, Chairman of Critical Outcome Technologies Inc. "We believe this to be important recognition for a key member of our team".

#### **About Critical Outcome Technologies Inc. (COTI)**

COTI is formed around a unique computational platform technology called CHEMSAS<sup>®</sup>, which allows for the accelerated identification, profiling and optimization of targeted small molecules potentially effective in the treatment of human diseases for which current therapy is either lacking or ineffective. COTI's business is focused on the discovery and pre-clinical development of libraries of optimized lead molecules for the treatment of specific cancers, HIV and multiple sclerosis. Currently, five targeted libraries of lead compounds (small cell lung cancer, multiple sclerosis, HIV integrase inhibitors, colorectal cancer, and acute myelogenous leukemia in adults) are under active development.

For more information, please visit our website [www.criticaloutcome.com](http://www.criticaloutcome.com) or contact:

**Contacts:**

Dr. Wayne Danter, President & CSO  
519-858-5157  
[wdanter@criticaloutcome.com](mailto:wdanter@criticaloutcome.com)

Gene Kelly, Chief Financial Officer  
519-858-5157  
[gkelly@criticaloutcome.com](mailto:gkelly@criticaloutcome.com)

*The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this news release.*